SB724, introduced in the Senate by Senator Cory Booker on February 25, 2025, would extend the temporary scheduling order for fentanyl-related substances by six months by amending the Emergency Scheduling framework established under Public Law 116-114. The extension preserves the current emergency-control regime without creating new substance classes or penalties, providing continuity while lawmakers consider longer-term policy changes.
It is a time-bound extension tied to the existing statutory mechanism and does not, by itself, alter the underlying schedule structure beyond changing the expiration date.
At a Glance
What It Does
The bill amends Section 2 of the Emergency Scheduling framework (Public Law 116-114) to replace the March 31, 2025 expiration with September 30, 2025, thereby extending the temporary scheduling order for fentanyl-related substances by six months.
Who It Affects
Federal agencies tasked with enforcement (e.g., DEA, DOJ), public health entities, healthcare providers, and laboratories handling fentanyl-related substances are directly affected by the extended regulatory window.
Why It Matters
The extension preserves regulatory control over fentanyl analogues during a critical period, allowing enforcement and public health efforts to continue while longer-term policy decisions are debated.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB724 is a targeted, time-limited renewal of the current emergency scheduling framework for fentanyl-related substances. By swapping the expiration date from March 31, 2025 to September 30, 2025, the bill keeps fentanyl-related substances temporarily scheduled under the existing law.
There are no new substance classes or penalties introduced by this measure; the core framework remains the same. This ensures continuity in enforcement and public health responses as Congress assesses longer-term policy options.
Because the extension operates within the emergency scheduling regime, it aligns with ongoing efforts to curb illicit supply and mitigate overdoses while avoiding a rushed, long-term policy change. The act itself is narrowly focused on the timing of scheduling rather than the substance classifications or regulatory penalties.
In short, SB724 buys time for policymakers while preserving the status quo for six more months.
The Five Things You Need to Know
The extension lasts six months.
Section 2 of Public Law 116-114 is amended to change the expiration date to September 30, 2025.
No new substances, penalties, or classifications are created by this bill.
The short title is the 'Temporary Extension of Fentanyl-Related Substances Scheduling Act.', Introduced in the Senate by Cory Booker on February 25, 2025.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
Section 1 provides the act’s citation as the 'Temporary Extension of Fentanyl-Related Substances Scheduling Act' for purposes of official references and citation in law and regulation.
Extension of Temporary Order for Fentanyl-Related Substances
Section 2, drawing on the Emergency Scheduling framework established by Public Law 116-114, amends the date by striking 'March 31, 2025' and inserting 'September 30, 2025'. This creates a six-month extension of the temporary scheduling order for fentanyl-related substances, maintaining the current regulatory and enforcement regime while Congress considers longer-term policy options.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- DEA and the Department of Justice maintain authority to enforce temporary scheduling and penalties for fentanyl-related substances.
- CDC and state/local public health departments can continue surveillance, prevention, and response activities within the extended scheduling window.
- Hospitals, emergency departments, and EMS providers benefit from regulatory continuity that supports overdose prevention and clinical management.
- Customs and border protection (CBP) and DHS personnel sustain tools to regulate importation of fentanyl-related substances.
- Communities in overdose-prone areas benefit from ongoing regulatory control that can limit illicit supply and exposure.
Who Bears the Cost
- Businesses handling fentanyl-related substances face ongoing compliance and reporting obligations within the extended window.
- Research laboratories and institutions studying fentanyl analogues confront continued regulatory oversight that can affect study protocols and data handling.
- Small businesses and distributors incur costs associated with maintaining compliance and training during the extension.
- Civil liberties groups may raise concerns about ongoing regulatory controls and due-process implications, even within a temporary framework.
Key Issues
The Core Tension
The central dilemma is whether to rely on a temporary, emergency scheduling extension to bridge the gap while longer-term policy is developed, or to adopt a more durable framework now that could have broader implications for research, medical use, and civil liberties.
The extension is narrowly tailored to extend an existing emergency scheduling mechanism rather than create new authorities or substance classifications. This preserves continuity in enforcement and public health response during a period when policy-makers are weighing longer-term approaches to fentanyl analogue control.
However, the measure defers deeper policy decisions and any substantive reform to a later date, potentially prolonging regulatory burdens on research and legitimate medical use. The reliance on a temporary, time-bound tool raises questions about when a more durable framework will be enacted and how oversight will be structured across agencies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.